Know the Roles of Remdesivir and IL-6 Inhibitors for COVID-19

May 2020

You’ll get questions about remdesivir or interleukin-6 (IL-6) inhibitors for hospitalized COVID-19 patients.

Remdesivir is an investigational IV antiviral with in vitro activity against the SARS-CoV-2 virus that causes COVID-19.

Observational data suggest improvements in oxygenation. And a recent trial in severe COVID-19 patients with pneumonia shows no benefit...but it was stopped early due to low enrollment.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Infectious Diseases Discourage Inappropriate Use of Hydroxychloroquine for COVID-19
Mental Health Offer Coping Strategies to Distressed Patients or Colleagues
Diabetes Meds Be Aware of SGLT2 Inhibitor Risks
Infectious Diseases Dispel Misinformation About Meds and Supplements for COVID-19
Practice Embrace Telemedicine as a Tool to Enhance Patient Care
Insomnia Explain That Insomnia Meds Are Only Modestly Helpful
Generics Understand Nuances About Generic Prescribing and Substitution
Gastroenterology Don’t Jump to Talicia for H. pylori Treatment
Allergic Reactions Know How to Determine if Med Containers Have Latex
Infectious Diseases Know the Roles of Remdesivir and IL-6 Inhibitors for COVID-19
Practice Streamline Med Profiles for Patients in Isolation
Antibiotics Be Ready to Monitor Vancomycin With AUC/MIC Goals
Infectious Diseases Put Inpatient Hydroxychloroquine Use for COVID-19 in Perspective

Know the Roles of Remdesivir and IL-6 Inhibitors for COVID-19

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents